EntreMed: Corporate Presentation (Entremed) - Jan 24, 2014 - "Phase 2 Trial Confirmed Safety and Antitumor Activity"; "Overall response rate - PR: 8%, - PR/SD: 58%, PFS 6: 22%"; "Stronger activities observed in clear cell ovarian cancer"; "Support further clinical trials in clear cell ovarian cancer"
P2 data • Oncology • Ovarian Cancer
|